Entity

Time filter

Source Type


Lokhov P.G.,RAS Institute of Chemistry | Voskresenskaya A.A.,RAS Institute of Chemistry | Trifonova O.P.,RAS Institute of Chemistry | Maslov D.L.,RAS Institute of Chemistry | And 3 more authors.
International Journal of Mass Spectrometry | Year: 2015

Recent decades have been marked by advances in omics sciences based on high-throughput technologies, which have enabled the measurement of enormous numbers of molecules in biosamples. This study investigated the capacity of blood plasma metabolome to be used for diagnostics. Blood plasma samples (n = 120) were methanol-treated to remove proteins. The remaining metabolite fractions were directly analyzed by mass spectrometry. Various diagnostic substances with different molecular weights, chemical classes, and plasma abundances were directly estimated from mass spectra or predicted from mass spectra by neural networking. Predicted levels of these substances were correlated (r = 0.51-0.78) with their actual values. Blood plasma metabolomics may be considered as a diagnostic tool capable of substituting for several clinical laboratory tests. © 2015 Elsevier B.V. All rights reserved. Source


Grigoryan O.R.,Endocrinological Scientific Center | Klinyshkova E.V.,City Clinical Hospital No. 31 | Andreeva E.N.,Endocrinological Scientific Center | Melnichenko G.A.,Endocrinological Scientific Center | Dedov I.I.,Endocrinological Scientific Center
Gynecological Endocrinology | Year: 2010

Aim.To evaluate the effect of the vaginally inserted hormone-releasing system 'NuvaRing®' on carbohydrate metabolism and acceptability (menstrual cycle control) of extended regimens of using as compared with the standard regimen (21/7) in women with type 1 diabetes mellitus (DM) in reproductive period during 24 months. Methods.The open randomised study included a total of 109 women with type 1 DM, using 'NuvaRing®' in different regimens (21/7, 42/7, 84/7 and 357/7). Average daily insulin requirements, the levels of glycosylated haemoglobin were determined at baseline, after 6, 12, 18 and 24 months of contraception. The control group was composed of 22 age-matched women with type 1 DM using no methods of contraception. Results.Using the contraceptive system 'NuvaRing®' in type 1 DM women in the reproductive period has proved to exert no clinically significant effect on carbohydrate metabolism in prolonged regimens, as well as in standard regimen. The overall number of bleeding days and spotting days was comparable in different groups. Longer regimens with fewer breaks were associated with fewer days of bleeding but a larger number of spotting days as compared with the shorter regimens, with a tendency towards a gradual decrease in spotting days during a year. Conclusion.The releasing system 'NuvaRing®' proved to be a reliable and safe means of contraception for late reproductive age women with type 1 DM. © 2010 Informa UK Ltd. Source

Discover hidden collaborations